These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 26251162)

  • 1. Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
    Kumar G; Uhrig D; Fowler S; DeLaney MC; Alexandrov AV
    CNS Drugs; 2015 Aug; 29(8):659-67. PubMed ID: 26251162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolytic therapy for acute ischemic stroke.
    Cornu C; Amsallem E; Serradj-Jaillard A A
    Am J Cardiovasc Drugs; 2001; 1(4):281-92. PubMed ID: 14728027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
    Carr SJ; Wang X; Olavarria VV; Lavados PM; Rodriguez JA; Kim JS; Lee TH; Lindley RI; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Woodward M; Chalmers J; Anderson CS; Robinson TG;
    Stroke; 2017 Sep; 48(9):2605-2609. PubMed ID: 28739832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
    Demaerschalk BM; Kleindorfer DO; Adeoye OM; Demchuk AM; Fugate JE; Grotta JC; Khalessi AA; Levy EI; Palesch YY; Prabhakaran S; Saposnik G; Saver JL; Smith EE;
    Stroke; 2016 Feb; 47(2):581-641. PubMed ID: 26696642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review.
    Sarmiento RJC; Diestro JDB; Espiritu AI; San Jose MCZ
    J Stroke Cerebrovasc Dis; 2019 Oct; 28(10):104290. PubMed ID: 31371140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA; Starr JA
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
    Hacke W; Kaste M; Bluhmki E; Brozman M; Dávalos A; Guidetti D; Larrue V; Lees KR; Medeghri Z; Machnig T; Schneider D; von Kummer R; Wahlgren N; Toni D;
    N Engl J Med; 2008 Sep; 359(13):1317-29. PubMed ID: 18815396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragility Index Meta-Analysis of Randomized Controlled Trials Shows Highly Robust Evidential Strength for Benefit of <3 Hour Intravenous Alteplase.
    Mun KT; Bonomo JB; Liebeskind DS; Saver JL
    Stroke; 2022 Jun; 53(6):2069-2074. PubMed ID: 35543129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Readministration of intravenous alteplase in acute ischemic stroke patients: case series and systematic review.
    Qureshi AI; Malik AA; Freese M; Thompson MJ; Khan AA; Suri MF
    Am J Emerg Med; 2015 Feb; 33(2):307.e1-4. PubMed ID: 25190550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke.
    Mandava P; Shah SD; Sarma AK; Kent TA
    Transl Stroke Res; 2015 Dec; 6(6):451-7. PubMed ID: 26385545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
    Jones ML; Holmes M
    Health Technol Assess; 2009 Sep; 13 Suppl 2():15-21. PubMed ID: 19804685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis of randomized and non-randomized studies.
    Ma Y; Xiang H; Busse JW; Yao M; Guo J; Ge L; Li B; Luo X; Mei F; Liu J; Wang Y; Liu Y; Li W; Zou K; Li L; Sun X
    J Neurol; 2024 May; 271(5):2309-2323. PubMed ID: 38436679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteplase: new indication. Inadequately assessed in ischaemic stroke.
    Prescrire Int; 2004 Aug; 13(72):127-31. PubMed ID: 15532135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
    Parsons M; Spratt N; Bivard A; Campbell B; Chung K; Miteff F; O'Brien B; Bladin C; McElduff P; Allen C; Bateman G; Donnan G; Davis S; Levi C
    N Engl J Med; 2012 Mar; 366(12):1099-107. PubMed ID: 22435369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data.
    Bluhmki E; Danays T; Biegert G; Hacke W; Lees KR
    Stroke; 2020 Aug; 51(8):2322-2331. PubMed ID: 32611284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
    Emberson J; Lees KR; Lyden P; Blackwell L; Albers G; Bluhmki E; Brott T; Cohen G; Davis S; Donnan G; Grotta J; Howard G; Kaste M; Koga M; von Kummer R; Lansberg M; Lindley RI; Murray G; Olivot JM; Parsons M; Tilley B; Toni D; Toyoda K; Wahlgren N; Wardlaw J; Whiteley W; del Zoppo GJ; Baigent C; Sandercock P; Hacke W;
    Lancet; 2014 Nov; 384(9958):1929-35. PubMed ID: 25106063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteplase for acute ischemic stroke.
    Gonzales NR; Grotta JC
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):301-18. PubMed ID: 16716092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
    Anderson CS; Robinson T; Lindley RI; Arima H; Lavados PM; Lee TH; Broderick JP; Chen X; Chen G; Sharma VK; Kim JS; Thang NH; Cao Y; Parsons MW; Levi C; Huang Y; Olavarría VV; Demchuk AM; Bath PM; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Ricci S; Roffe C; Pandian J; Billot L; Woodward M; Li Q; Wang X; Wang J; Chalmers J;
    N Engl J Med; 2016 Jun; 374(24):2313-23. PubMed ID: 27161018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.